Predicting Effective Therapy in Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-24

Study Completion Date

2026-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity

NCT03821870

Metastatic Pancreatic Cancer

COMPLETED

Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma

NCT01474564

Pancreatic Adenocarcinoma

COMPLETED

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

NCT03334708

Pancreatic Cancer Pancreatic Diseases Pancreatitis +1 more

RECRUITING

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

NCT00003810

Pancreatic Cancer

COMPLETED PHASE2

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

NCT03060720

Pancreatic Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer Pancreatic Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Stage IV Pancreatic Cancer

CTC isolocation and analysis

Intervention Type DIAGNOSTIC_TEST

Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTC isolocation and analysis

Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
* Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
* Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
* ECOG performance status 0-2.
* A minimum age of 18 years old.

Exclusion Criteria

* Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
* Known to be HIV positive on antiretroviral therapy
* Prior organ allograft
* Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No